Abstract
Purpose
The study aims to establish population pharmacokinetic (PPK) models of lamotrigine (LTG) in different age groups of epileptic children by nonlinear mixed effect modelling(NONMEM), and provide essential tools and theoretical basis for individualised optimal drug dose.
Methods
Cases of 473 epileptic children were divided into infant, toddler and preschool age (≤6 years) (n = 211), school age (6–12 years) (n = 171) and adolescence age (>12 years) (n = 81). A total of 625 steady-state serum trough concentration samples were extracted. The clinical information included demography, medication, serum concentration data and blood biochemical parameters. PPK models of LTG were established by NONMEM program, using first-order absorption and elimination. Demography and drug combination was investigated for influence on apparent clearance (CL) and apparent volume of distribution (Vd). To assess the accuracy and precision of the different ages and whole-age model, the mean prediction error (MPE), mean absolute error (MAE) and root mean squared error (RMSE) were compared.
Results
The final model of LTG in different ages stage and whole age was as follows: (1) infant, toddler and preschool age CL = 0.715 × [(WEIG/16.25)0.655] × (0.458VPA) × (1.99IND), V = 10.4; (2) school age CL(L/h) = 1.01 × (WEIG/30)0.399 × 0.465VPA × 1.98IND, Vd(L) = 17.7; (3) adolescence age CL(L/h) = 1.49 × (WEIG/51.5)0.509 × 0.498VPA × 1.7IND, Vd(L) = 23.1; (4) whole age CL = 0.945 × [(WEIG/25)0.645] × (0.463VPA) × (1.94IND), V = 16.7 × (WEIG/25)0.919 (WEIG, total body weight; VPA, combination with valproate, yes = 1, no = 0; IND, combination with enzyme inducer, yes = 1, no = 0). The values of MPE, MAE and RMSE in age-stage-specific models were less than the ones in the whole-age model, which suggests the age-stage-specific models have better precision and accuracy than the whole-age model.
Conclusion
PPK models of LTG in different age groups of epileptic children were successfully established. Weight and combination therapy were identified as significant covariates on LTG clearance. Compared with the whole-age model, the age-specific models are more reliable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Reference
Whiting B, Kelman AW, Grevel J (1986) Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet 11(5):387–401
Serrano BB, Garcia SMJ, Otero MJ et al (1999) Valproate population pharmacokinetics in children. J Clin Pharm Ther 24(1):73–80
Correa T, Rodriguez I, Romano S (2008) Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos 29(9):511–520
Wang YH, Wang L, Lu W et al (2012) Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. Acta Pharmacol Sin 33(6):845–851
Wang Y, Zhang HN, Niu CH et al (2014) Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin 35(10):1342–1350
Goa KL, Ross SR, Chrisp P (1993) Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46(1):152–176
Morris RG, Black AB, Harris AL et al (1998) Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 46(6):547–551
Chong E, Dupuis LL (2002) Therapeutic drug monitoring of lamotrigine. Ann Pharmacother 36(5):917–920
Chen C (2000) Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. Br J Clin Pharmacol 50(2):135–145
Milovanovic JR, Jankovic SM (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47(12):752–760
Zhang S, Wang L, Lu W (2008) Population pharmacokinetics of lamotrigine in Chinese children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 10(2):105–109
He DK, Wang L, Qin J et al (2012) Population pharmacokinetics of lamotrigine in Chinese children with epilepsy. Acta Pharmacol Sin 33(11):1417–1423
Mallaysamy S, Johnson MG, Rao PG et al (2013) Population pharmacokinetics of lamotrigine in Indian epileptic patients. Eur J Clin Pharmacol 69(1):43–52
Brzakovic B, Vucicevic K, Kovacevic SV et al (2014) Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients—nonlinear mixed effects modelling approach. Eur J Clin Pharmacol 70(2):179–185
Grasela TH, Fiedler-Kelly J, Cox E et al (1999) Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 39(4):373–384
Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165(12):819–829
Gidal BE, Anderson GD, Rutecki PR et al (2000) Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res 42(1):23–31
Kearns GL, Abdel-Rahman SM, Alander SW et al (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157–1167
Acknowledgements
Prof. Wei Zhao (Shandong University, Jinan, China) assisted us with the design of this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Zb., Ji, Sm., Han, Y. et al. Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy. Eur J Clin Pharmacol 73, 445–453 (2017). https://doi.org/10.1007/s00228-016-2190-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-016-2190-2